NOVELION THERAPEUTICS (QLTI) saw its loss widen to $20.12 million, or $1.50 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $3.68 million, or $0.35 a share. On an adjusted basis, net loss for the quarter was $23.09 million, when compared with $23.84 million in the last year period.

Revenues for the quarter were $13.57 million. The company has not recorded any revenues for the previous year period. Gross margin for the quarter was at 43.35 percent.

Operating loss for the quarter was $16.51 million, compared with an operating loss of $3.81 million in the previous year period.

"The transformative steps we took in 2016 to realign costs and refocus and intensify our commercial efforts have set us on a strong growth trajectory," said Mary Szela, chief executive officer of Novelion. "Armed with a portfolio of marketed and innovative development-stage products for rare diseases, and with a pathway to potential new disease indications and commercial markets, we expect to further develop our leadership position in rare metabolic and cardiovascular diseases. In addition to intensifying our commercial efforts around MYALEPT and JUXTAPID, both in the U.S. and globally, we are exploring new opportunities for metreleptin in a range of low leptin-mediated metabolic rare diseases representing significant unmet medical needs, and we will provide an update on our program prioritization efforts in mid-2017."